InVivo Therapeutics Receives FDA Conditional Approval for Proposed Protocol Changes
December 26, 2013 at 14:03 PM EST
InVivo Therapeutics (OTC: NVIV ) announced today that it has received conditional approval from the Food and Drug Administration for proposed changes to the protocol and supporting documents for the